Notably, CTXD14SkM-EV treatment significantly reduced NF-κB and pNF-κB protein levels in ALS-affected muscle by approximately 50%, bringing them closer to baseline levels observed in WT mice (Figure 6A–C). This evidence concerns the gene NFKB1 and amyotrophic lateral sclerosis.